Kansas Governor Kathleen Sebelius is confirmed as HHS Secretary.
Kansas Governor Kathleen Sebelius has been confirmed and sworn in as the next Secretary of the U.S. Department of Health and Human Services (HHS).
“It is an honor to lead the Department of Health and Human Services, and I am grateful for the opportunity to serve at such a pivotal moment in our history,” she said in a statement.Secretary Sebelius has more than 20 years of experience in state government, and has been a leader on healthcare issues for over a decade. She was first elected governor of Kansas in 2003 and was re-elected in 2006.
In response to the announcement, Scott P. Serota, president and CEO of the Blue Cross and Blue Shield Assn. (BCBSA), issued a statement supporting the confirmation.
“Secretary Sebelius has long been an advocate of expanding access and making healthcare more affordable. We look forward to working with her, the Obama administration and members of Congress on comprehensive healthcare reform this year that builds on the existing employer-based system of coverage to expand coverage to all Americans and improve quality while reining-in costs,” Serota said.
At a recent House Ways and Means Committee hearing, Sebelius stressed the importance of health IT interoperability, as well as the importance of including adequate privacy protections for health data.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More